Guardant Health
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 31
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
29% more capital invested
Capital invested by funds: $2.84B [Q3] → $3.65B (+$812M) [Q4]
10% more funds holding
Funds holding: 267 [Q3] → 295 (+28) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 89
6.09% less ownership
Funds ownership: 102.8% [Q3] → 96.71% (-6.09%) [Q4]
48% less call options, than puts
Call options by funds: $29.5M | Put options by funds: $56.8M
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
18%
upside
Avg. target
$55
30%
upside
High target
$60
41%
upside
11 analyst ratings
11 positive
100%
0 neutral
0%
0 negative
0%
Stephens & Co. Mason Carrico 18% 1-year accuracy 5 / 28 met price target | 30%upside $55 | Overweight Reiterated | 26 Mar 2025 |
Morgan Stanley Shannon O'Callaghan 100% 1-year accuracy 1 / 1 met price target | 22%upside $52 | Overweight Maintained | 6 Mar 2025 |
Piper Sandler David Westenberg 44% 1-year accuracy 19 / 43 met price target | 18%upside $50 | Overweight Maintained | 26 Feb 2025 |
Guggenheim Subbu Nambi 19% 1-year accuracy 3 / 16 met price target | 32%upside $56 | Buy Reiterated | 24 Feb 2025 |
Scotiabank Sung Ji Nam 12% 1-year accuracy 3 / 25 met price target | 22%upside $52 | Sector Outperform Maintained | 24 Feb 2025 |
Financial journalist opinion
Based on 5 articles about GH published over the past 30 days
Neutral
MarketBeat
3 days ago
4 Healthcare Stocks With Massive Gains—and More to Come
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Neutral
Business Wire
1 week ago
Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare.
Positive
Seeking Alpha
2 weeks ago
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently generating record revenues and growth for GH. Similarly, GH has an expanding pipeline, which includes its Reveal and Shield tests, that could significantly boost its future market potential.
Positive
Benzinga
3 weeks ago
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CRC) screening.
Neutral
Business Wire
3 weeks ago
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield™ blood test for colorectal cancer (CRC) screening. The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening. Medicare already covers the test. The CMS determination confirms.
Neutral
Business Wire
1 month ago
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of Febr.
Neutral
Business Wire
1 month ago
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases, this is due to patient fear and anxiety, but a blood test option offers hope to increase screening rates. Conduct.
Positive
Zacks Investment Research
1 month ago
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Positive
Benzinga
1 month ago
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents.
Neutral
Seeking Alpha
1 month ago
Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Patrick Donnelly - Citi Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JPMorgan Kyle Mikson - Canaccord Mason Carrico - Stephens Inc. Matt Sykes - Goldman Sachs Operator Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call.
Charts implemented using Lightweight Charts™